γ-Aminobutyric Acid Promotes Osteogenic Differentiation of Mesenchymal Stem Cells by Inducing TNFAIP3

Author(s): Hanwen Li, Yongyao Wu, Ning Huang, Qi Zhao, Quan Yuan*, Bin Shao*

Journal Name: Current Gene Therapy

Volume 20 , Issue 2 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Osteoporosis is the most common metabolic bone disease. There is still an unmet need for novel therapeutic agents that could be beneficial as osteoporosis treatments. It has been reported that the neurotransmitter γ-aminobutyric acid (GABA) might be associated with human bone formation. However, the precise mechanism remains unclear.

Objective: To investigate the effect of GABA on bone metabolism and explore the possible role of TNFAIP3 in this process.

Methods: GABA had little effect on the proliferation of human mesenchymal stem cells (hMSCs) and RAW 264.7 cells, as indicated by the cell counting kit-8 (CCK-8) assay. The results showed that GABA enhanced the intensity of ALP staining, ALP activity, and accumulation of Ca2+ mineralized nodules in hMSCs during osteogenic induction.

Results: The qRT-PCR results indicated that GABA treatment significantly increased the mRNA expression of osteogenic genes in hMSCs. In RAW 264.7 cells, TRAP staining showed that GABA did not alter the number or size of osteoclasts or the expression of osteoclastic genes, which suggests that GABA does not affect osteoclastic differentiation. Mechanistically, GABA treatment significantly induced the sustained expression of TNFAIP3. Furthermore, by knocking down TNFAIP3, the osteogenic effect of GABA was antagonized, which suggests that TNFAIP3 mediates the effects of GABA in hMSCs.

Conclusion: Our results suggested that GABA treatment positively regulated osteogenic differentiation by upregulating TNFAIP3, while no obvious effect on osteoclastic differentiation was detected. Therefore, our results provide a potential gene therapy for the treatment of osteoporosis and low bone mineral density.

Keywords: GABA, osteoporosis, osteoblasts, osteoclasts, MSCs, TNFAIP3.

[1]
Seeman E, Martin TJ. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat Rev Rheumatol 2019; 15(4): 225-36.
[http://dx.doi.org/10.1038/s41584-019-0172-3] [PMID: 30755735]
[2]
Yang Y-S, Xie J, Wang D, et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat Commun 2019; 10(1): 2958.
[http://dx.doi.org/10.1038/s41467-019-10809-6] [PMID: 31273195]
[3]
Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003; 423(6937): 349-55.
[http://dx.doi.org/10.1038/nature01660] [PMID: 12748654]
[4]
Borumandi F, Aghaloo T, Cascarini L, Gaggl A, Fasanmade K. Anti-resorptive drugs and their impact on maxillofacial bone among cancer patients. Anticancer Agents Med Chem 2015; 15(6): 736-43.
[http://dx.doi.org/10.2174/1871520615666150325232857] [PMID: 25807940]
[5]
Kraenzlin ME, Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 2011; 7(11): 647-56.
[http://dx.doi.org/10.1038/nrendo.2011.108] [PMID: 21750510]
[6]
Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 2013; 85(10): 1417-23.
[http://dx.doi.org/10.1016/j.bcp.2013.03.002] [PMID: 23500550]
[7]
Auger ML, Meccia J, Phillips AG, Floresco SB. Amelioration of cognitive impairments induced by GABA hypofunction in the male rat prefrontal cortex by direct and indirect dopamine D1 agonists SKF-81297 and d-Govadine. Neuropharmacology 2020; 16, 2107844
[http://dx.doi.org/10.1016/j.neuropharm.2019.107844] [PMID: 31704272]
[8]
Song Y, Shenwu M, Dhossche DM, Liu YM. A capillary liquid chromatographic/tandem mass spectrometric method for the quantification of γ-aminobutyric acid in human plasma and cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 814(2): 295-302.
[http://dx.doi.org/10.1016/j.jchromb.2004.10.046] [PMID: 15639451]
[9]
Jiménez-Jiménez FJ, Molina JA, Gómez P, et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer’s disease. J Neural Transm (Vienna) 1998; 105(2-3): 269-77.
[http://dx.doi.org/10.1007/s007020050056] [PMID: 9660105]
[10]
Jembrek MJ, Vlainic J. GABA Receptors: Pharmacological Potential and Pitfalls. Curr Pharm Des 2015; 21(34): 4943-59.
[http://dx.doi.org/10.2174/1381612821666150914121624] [PMID: 26365137]
[11]
Meldrum B. Epilepsy and gamma-aminobutyric acid-induced inhibition. Int Rev Neurobiol 1975; 17.
[12]
Nutt D. GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med 2006; 2(2): S7-S11.
[http://dx.doi.org/10.5664/jcsm.26525] [PMID: 17557501]
[13]
Khuhawar MY, Rajper AD. Liquid chromatographic determination of γ-aminobutyric acid in cerebrospinal fluid using 2-hydroxynaphthaldehyde as derivatizing reagent. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 788(2): 413-8.
[http://dx.doi.org/10.1016/S1570-0232(03)00062-X] [PMID: 12705983]
[14]
Dhossche D, et al. Elevated plasma gama-aminobutyric acid (GABA) levels in autistic youngsters: Stimulus for GABA hypothesis of autism. Medical Science Monitor, 8, PR1-PR6. Med Sci Monit 2002; 8: PR1-6.
[PMID: 12165753]
[15]
Hwang I, et al. GABA-stimulated adipose-derived stem cells suppress subcutaneous adipose inflammation in obesity. PPNAS 2019; 116(24): 11936-45.
[http://dx.doi.org/10.1073/pnas.1822067116]
[16]
Bhat R, Axtell R, Mitra A, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci USA 2010; 107(6): 2580-5.
[http://dx.doi.org/10.1073/pnas.0915139107] [PMID: 20133656]
[17]
Kenmogne LC, Maltais R, Poirier D. Synthesis of a dansyl-labeled inhibitor of 17β-hydroxysteroid dehydrogenase type 3 for optical imaging. Bioorg Med Chem Lett 2018; 26: 2179-83.
[http://dx.doi.org/10.1016/j.bmcl.2016.03.069] [PMID: 27025340]
[18]
Walsh JS, Eastell R. Osteoporosis in men. Nat Rev Endocrinol 2013; 9(11): 637-45.
[http://dx.doi.org/10.1038/nrendo.2013.171] [PMID: 24019112]
[19]
Wang Z, Bian L, Mo C, et al. Quantification of aminobutyric acids and their clinical applications as biomarkers for osteoporosis. Commun Biol 2020; 3(1): 39.
[http://dx.doi.org/10.1038/s42003-020-0766-y] [PMID: 31969651]
[20]
Djigoue G-B, Simard M, Kenmogne L-C, Poirier D. Two androsterone derivatives as inhibitors of androgen biosynthesis. Acta Crystallogr 2013; C68: 231-4.
[http://dx.doi.org/10.1107/S0108270112021099] [PMID: 22669194]
[21]
Fujimori S, Hinoi E, Yoneda Y. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorg Med Chem 2002; 19: 4652-68.
[http://dx.doi.org/10.1016/S0006-291X(02)00405-9]
[22]
Takahata Y, Takarada T, Hinoi E, Nakamura Y, Fujita H, Yoneda Y. Osteoblastic γ-aminobutyric acid, type B receptors negatively regulate osteoblastogenesis toward disturbance of osteoclastogenesis mediated by receptor activator of nuclear factor κB ligand in mouse bone. J Biol Chem 2011; 286(38): 32906-17.
[http://dx.doi.org/10.1074/jbc.M111.253526] [PMID: 21828041]
[23]
Dixit VM, Green S, Sarma V, et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem 1990; 265(5): 2973-8.
[PMID: 2406243]
[24]
Chang J, Liu F, Lee M, et al. NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci USA 2013; 110(23): 9469-74.
[http://dx.doi.org/10.1073/pnas.1300532110] [PMID: 23690607]
[25]
Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol 2014; 35(1): 22-31.
[http://dx.doi.org/10.1016/j.it.2013.10.005] [PMID: 24246475]
[26]
Martens A, van Loo G. A20 at the Crossroads of Cell Death, Inflammation, and Autoimmunity. Cold Spring Harb Perspect Biol 2020; 12(1) 036418
[http://dx.doi.org/10.1101/cshperspect.a036418] [PMID: 31427375]
[27]
Savino S, Ferrandi EE, Forneris F, et al. Structural and biochemical insights into 7beta-hydroxysteroid dehydrogenase stereoselectivity. Proteins 2010; 84: 859-65.
[28]
Matmati M, Jacques P, Maelfait J, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011; 43(9): 908-12.
[http://dx.doi.org/10.1038/ng.874] [PMID: 21841782]
[29]
Voet S, Mc Guire C, Hagemeyer N, et al. A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation. Nat Commun 2018; 9(1): 2036.
[http://dx.doi.org/10.1038/s41467-018-04376-5] [PMID: 29789522]
[30]
Hammer GE, Turer EE, Taylor KE, et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2011; 12(12): 1184-93.
[http://dx.doi.org/10.1038/ni.2135] [PMID: 22019834]
[31]
Aeschlimann FA, et al. A method to identify protein sequences that fold into a known three-dimensional structure. Science 2018; 253: 164-70.
[http://dx.doi.org/10.1126/science.1853201 ] [PMID: 1853201]
[32]
Razani B, Whang MI, Kim FS, et al. Non-catalytic ubiquitin binding by A20 prevents psoriatic arthritis-like disease and inflammation. Nat Immunol 2020; 21(4): 422-33.
[http://dx.doi.org/10.1038/s41590-020-0634-4] [PMID: 32205880]
[33]
Polykratis A, Martens A, Eren RO, et al. A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain. Nat Cell Biol 2019; 21(6): 731-42.
[http://dx.doi.org/10.1038/s41556-019-0324-3] [PMID: 31086261]
[34]
Garg AV, Ahmed M, Vallejo AN, Ma A, Gaffen SL. The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci Signal 2013; 6(278): ra44-.
[http://dx.doi.org/10.1126/scisignal.2003699] [PMID: 23737552]
[35]
Afonina IS, Zhong Z, Karin M, Beyaert R. Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome. Nat Immunol 2017; 18(8): 861-9.
[http://dx.doi.org/10.1038/ni.3772] [PMID: 28722711]
[36]
Kiessling CY, Lanza K, Feinberg E, Bishop C. Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats. Neuropharmacology 2020; 17, 4108138
[http://dx.doi.org/10.1016/j.neuropharm.2020.108138] [PMID: 32492451]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 2
Year: 2020
Published on: 17 September, 2020
Page: [152 - 161]
Pages: 10
DOI: 10.2174/1566523220999200727122502
Price: $65

Article Metrics

PDF: 21
HTML: 2